Harpoon Therapeutics — Technical Presentation (May 2020)
49 slides from Harpoon Therapeutics's technical presentation, May 29, 2020
Slide 1: HPN424 Interim Data Presentation and Pipeline Update
Spearheading Immunotherapies Phase 1 HPN424 Interim Data Presentation and Pipeline Update May 29, 2020 Exhibit 99.2
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements about Harpoon Therapeutics, Inc.. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements about our financial position, strategy, expe
Slide 3: Harpoon Therapeutics – Investment Overview
Therapeutic Focus Clinical-stage immunotherapy company Platform Technologies T cell engager technology, “off-the-shelf” therapies for solid tumors -TriTAC: Tri-specific T cell Activating Construct platform -ProTriTAC: Pro-drug form of TriTAC Multiple Product Candidates HPN424 (PSMA TriTAC) Phase 1 i
Slide 4: Broad Pipeline of Immuno-Oncology Programs
Product Candidate Target / Indication Stage of Development Anticipated Milestones Preclinical Phase 1 Phase 2 HPN424 PSMA / Prostate cancer Interim data presented at ASCO; anticipate expansion study in 2020 HPN536 MSLN / Ovarian, pancreatic and other solid tumors April 2019: Initiated Phase 1/2a cli
Slide 5: TriTAC: Small Size and Flexibility, Albumin Domain Confers Extended Half Life
BiTE ~50kD TriTAC ~50kD Bispecific Antibody ~150kD Molecular Weight TriTAC: Small Size and Flexibility, Albumin Domain Confers Extended Half Life Molecular Structure HSA – human serum albumin, BiTE – bispecific T cell engager
Slide 6: TriTACs Overcome Immune Escape Mechanisms and Induce Killing Independent of MHC Expression
Target Cell T Cell Does not require MHC expression for recognition by T cell Does not require a T cell clone with specific T cell receptor Any T cell can recognize a surface antigen TCR Complex TriTAC® X X MHC MHC downregulation and mutations are a major tumor evasion mechanism TriTACs Overcome Immu
Slide 7: Interim Analysis: Phase 1 Study of HPN424 in Patients with mCRPC
Interim Analysis: Phase 1 Study of HPN424 in Patients with mCRPC Natalie Sacks, M.D., Chief Medical Officer
Slide 8: Metastatic Prostate Cancer: >$5B Global Market Opportunity
Metastatic Prostate Cancer: >$5B Global Market Opportunity* Source: SEER, ACS, 2019 estimates ~ 174K new cases of prostate cancer annually in the U.S. >31K U.S. deaths per year (2nd leading cause of cancer death in men) Mean survival time for mCRPC = 13 months 5-year survival rate is ~30% in more ag
Slide 9: HPN424 Targets PSMA - A Highly Expressed and Validated Target for Prostate Cancer
HPN424 Targets PSMA - A Highly Expressed and Validated Target for Prostate Cancer Designed to bind to human PSMA, CD3, and albumin Redirects T cells to kill PSMA-expressing target cells Target overexpressed in malignant cells, with limited expression in normal tissue Clinically validated by encourag
Slide 10: Authors
Authors Johanna Bendell, MD1, Lawrence Fong, MD2, Mark Stein, MD3, Tomasz M. Beer, MD4, Ashley Ross, MD, PhD5, Xin Gao, MD6, Aaron Weitzman, MD, FACP7, Richard Austin, PhD8, Vaishnavi Ganti, PhD8, Che-Leung Law, PhD8, Bryan Lemon, PhD8, Holger Wesche, PhD8, Johann de Bono, MD9 1Sarah Cannon Research
Slide 11: Phase 1 Study Design
Target Population Metastatic castration-resistant prostate cancer (mCRPC) Disease progression on the prior systemic regimen At least two prior systemic therapies approved for mCRPC Prior chemotherapy allowed, but not required Trial Design Key objectives include characterization of safety, tolerabili
Slide 12: Baseline Characteristics and Demographics (n=44)
Table 1. Baseline Characteristics and Demographics (n=44) Age (Years) Median 71 Range 44 - 91 Race White 34 (77%) Black or African American 5 (11%) Asian 1 (2%) Other / Not reported 4 (9%) ECOG Performance Status 0 26 (59%) 1 18 (41%) PSA (ng/mL) Mean 649 Median 244 Range 0.1 - 5000 LDH (U/L) Mean 4
Slide 13: Adverse Events (CTCAE v5.0) in >10% of Patients by Grade
Table 2. Adverse Events (CTCAE* v5.0) in >10% of Patients by Grade, Regardless of Relationship All CRS events resolved and patients were successfully re-treated High-grade transaminitis was observed primarily in the setting of CRS; abnormalities were transient, no clinical sequelae Short-term premed
Slide 14: Kinetics of Serum Cytokine/Chemokine Levels
Kinetics of Serum Cytokine/Chemokine Levels N = 4 patients dosed at 12 ng/kg (no dex pretreatment) 16 cytokines evaluated Post treatment transient increase in IL-6, IL-8 , as well as IL-5, IL-10, MCP, IFNγ, TNFα, MIP-1α, MIP-1β (not shown) at 12 ng/kg doses Spikes are transient and attenuate after f
Slide 15: Cytokine Spikes Managed with Dexamethasone
Dose-dependent, transient increases in peripheral cytokine and chemokine levels were observed, in the absence of dexamethasone premedication Transient cytokine increases can be effectively managed with short-term dexamethasone premedication Cytokine Spikes Managed with Dexamethasone Figure 8. Cytoki
Slide 16: Dexamethasone Premedication and Taper by Cohort
HPN424 was initiated at 1.3ng/kg with no dexamethasone (dex) premedication Dose-dependent, transient increases in serum cytokine and chemokines were observed in early cohorts 2 patients who received 24ng/kg with no dex premed experienced Grade 3 CRS; patients were subsequently administered dex preme
Slide 17: Patient Time on Treatment
Figure 3. Patient Time on Treatment 11 of 28 patients (39%) with > 18 weeks follow-up remained on study beyond week 18 8 of 26 (31%) patients remained on study > 24 weeks Of the 8 patients on study > 24 weeks, 7 patients (88%) continued on HPN424 treatment longer than the time on their most recent p
Slide 18: Patient PSA Values on Treatment
HPN424-1001 Phase 1 Dose Escalation Figure 4. Patient PSA Values on Treatment Patients with PSA declines during course of treatment Eight patients had PSA decreases from baseline ranging from -3.8% to -76%, including 2 patients with PSA decline >50% from baseline PSA declines observed in patients ac
Slide 19: Patients with PSA Reductions Post-Baseline
Patients with PSA Reductions Post-Baseline * * Remain On Study ↑12ng/kg ↑40ng/kg ↑72ng/kg ↑ Dose increase
Slide 20: Patient Profile – Patient 003 - Ongoing
Patient 003, a 69-year old male, diagnosed March 2013 Patient initiated HPN424 at 12ng/kg and escalated twice to 40 then 72 ng/kg Patient demonstrated early rise in PSA followed by a steady decline starting Week 12, currently -9% PSA decline from baseline Drop in LDH from 2361 to 241 U/L observed, c
Slide 21: Patient Profile – Patient 024 - Ongoing
Patient Profile – Patient 024 - Ongoing Patient 024, a 76-year old male, diagnosed December 2009 Patient initiated HPN424 at 54ng/kg with a 6-week dexamethasone taper Patient demonstrated early rise in PSA followed by a slight decline starting Week 15 Patient remains on study after 38 weeks of treat
Slide 22: Median Concentration Time Profile for HPN424
Figure 7. Median Concentration Time Profile for HPN424 in Given Dose Range of 1.3 – 96ng/kg HPN424 demonstrated dose proportional increase in Cmax and AUC with a geometric median T1/2 of 24.9 hours (range: 9.0 – 312 hours) Median clearance (CL) and volume of distribution (Vss) for HPN424 in the give
Slide 23: Dose-Dependent Increase in Cmax
Dose-Dependent Increase in Cmax Median Cmax (ng/mL) Dose (ng/kg) C1D1 EOI for 1.3 ng/kg – 96 ng/kg cohorts
Slide 24: Low Frequency ADA Response to HPN424
Low Frequency ADA Response to HPN424 ADA = Anti-drug antibodies nAb = neutralizing ADANA = not applicable Pt 001 Pt 002 Pt 003 Pt 005 Pt 006 Pt 007 Pt 009 Pt 010 Pt 011 Pt 012 Pt 013 Pt 014 Pt 015 Pt 016 ADA – – – – – – – + Pre-existing – – – – – – nAb NA NA NA NA NA NA NA + C7D1 NA NA NA NA NA NA P
Slide 25: Reduction in Circulating Tumor Cells
Reduction in circulating tumor cells (CTCs) was seen in 12 of 27 patients with available CTC counts collected on C1D1 predose (baseline) and C1D15 predose (after 2 doses of HPN424) Figure 9. Post Treatment Changes in Circulating Tumor Cell Figure 9. Post Treatment Changes in Circulating Tumor Cells
Slide 26: HPN424-Mediated T Cell Margination
HPN424-Mediated T Cell Margination Transient T cell margination from circulation, peaking around 5 hrs post infusions and returning to baseline after about 48 hrs, indicating T cell activation Similar trends observed in CD4 helper T and CD8 cytotoxic T cell subsets T cell margination also observed i
Slide 27: HPN424-1001 Phase 1 Dose Escalation Summary
HPN424-1001 Phase 1 Dose Escalation Summary HPN424 represents a novel half-life extended PSMA-targeting T cell engager that can be safely administered once weekly Dose escalation comprises a heterogeneous, heavily pretreated population Evidence of half-life extension supports once weekly HPN424 admi
Slide 28: HPN536 and Other Product Candidates
HPN536 and Other Product Candidates Jerry McMahon, Ph.D., President and CEO
Slide 29: MSLN - Associated with Tumors with High Unmet Need and Low Survival Rates
MSLN - Associated with Tumors with High Unmet Need and Low Survival Rates 60-65% 80-85% 85-90% 60-65%2 34-42% MSLN Expression Level (%)1 22,500 57,000 2,600 200,0003 40,0004 Annual Incidence (U.S.) Over 80,000 new patients diagnosed each year in U.S. with solid tumors known to have high MSLN express
Slide 30: HPN536 – Targets MSLN for Treatment of Ovarian Cancer, Pancreatic, Mesothelioma
HPN536 – Targets MSLN for the Treatment of Ovarian Cancer, Pancreatic, Mesothelioma and Other MSLN-Expressing Tumors HPN536 is a tri-specific single chain molecule of ~50 kDa Mesothelin Expressing Target MSLN CD3 anti-MSLN anti-albumin anti-CD3ε Target antigen T cell Designed to bind to human mesoth
Slide 31: HPN536 – Design of Open-label Ongoing Phase 1/2a Trial
Dose escalation: single patient Dose escalation: 3 + 3 (3 – 6 pts per dose level) MTD or recommended Phase 2 dose Part 1 – Dose Escalation Part 2 – Expansion 3 parallel cohorts, ~20 patients each: Ovarian, Pancreatic and Mesothelioma cancers Treated at recommended Phase 2 dose determined in Part 1 ³
Slide 32: Summary HPN536 Phase 1/2a Dose Escalation
Summary HPN536 Phase 1/2a Dose Escalation Cohort Dose (ng/kg) N Tumor Types Treated 1 6* 1 Ovarian 2 18* 1 Ovarian 3 54* 1 Ovarian 4 68 6 4 Ovarian, 2 Pancreatic 5 90 7 5 Ovarian, 2 Pancreatic 6 120 5 2 Ovarian, 3 Pancreatic 7 160 3 1 Ovarian, 2 Pancreatic 8 (Currently Enrolling) 210 1 1 Pancreatic
Slide 33: Dose Proportional Increase in Cmax
Dose Proportional Increase in Cmax HPN536 serum concentration at end of infusion on C1D1 (first dose) 6 ng/kg to 160 ng/kg cohorts
Slide 34: PK Profile: Half-Life Extension & Linear Kinetics
PK Profile: Half-Life Extension & Linear Kinetics Serum HPN536 (ng/mL) Time (hours) Dose proportional increase in AUC with an overall median T1/2 of 87.4 hours (38.1 – 137 hours) Dose independent clearance and volume of distribution, indicating linear kinetics No apparent difference in PK parameters
Slide 35: HPN536 Program Summary
HPN536 Program Summary Phase 1/2a trial currently in dose escalation, progressing well 25 patients treated to-date across 8 cohorts (6 – 210ng/kg) 15 ovarian, 10 pancreatic cancer patients enrolled Adverse events have been transient, manageable and consistent with expected mechanism of action 1 even
Slide 36: HPN217: Treatment for Multiple Myeloma
Multiple myeloma is the 2nd most prevalent blood cancer in U.S. Constitutes over 40% of U.S./global heme-onc market, with significant projected growth Despite many currently approved therapies, patients ultimately relapse and new treatment options needed for disease control BCMA is a clinically vali
Slide 37: HPN217 - Targets BCMA for Multiple Myeloma and Other BCMA-Expressing Tumors
HPN217 - Targets BCMA for the Treatment of Multiple Myeloma and Other BCMA-Expressing Tumors Designed to bind to human BCMA, CD3, and albumin Redirects T cells to kill BCMA-expressing target cells Covered by global licensing and option agreement with AbbVie Possible license after completion of Phase
Slide 38: HPN217 Phase 1/2 Trial Design
Dose escalation: single patient Dose escalation: 3 + 3 (3 – 6 pts per dose level) MTD or recommended Phase 2 dose Part 1 – Dose Escalation Part 2 – Expansion Cohort treated at recommended Phase 2 dose determined in Part 1 ³ Gr 2 study drug related toxicity Trial design optimized for rapid developmen
Slide 39: HPN328 - Targets DLL3 for Treatment of Small Cell Lung Cancer
HPN328 - Targets DLL3 for the Treatment of Small Cell Lung Cancer Designed to bind to human DLL3, CD3, and albumin Redirects T cells to kill DLL3-expressing target cells Preclinical data presentation at AACR-NCI-EORTC (Oct 2019), shows strong tumor cell killing in cell-based and animal SCLC models a
Slide 40: HPN328 – Treatment for SCLC and Other Neuroendocrine Tumors
Initial target for Small Cell Lung Cancer, remains an unmet medical need Aggressive disease with limited treatment options 15% of all lung cancers addressable by targeting DLL3 Emerging data indicating DLL3 expression in other neuroendocrine tumors besides SCLC DLL3 as a promising target for T-cell
Slide 41: ProTriTAC: A Novel Prodrug Technology Platform
ProTriTAC: A Novel Prodrug Technology Platform Holger Wesche, Ph.D., Chief Scientific Officer
Slide 42: ProTriTAC: T Cell Engager Prodrug Platform
ProTriTAC: T Cell Engager Prodrug Platform to Target More Broadly Expressed Tumor Antigens Goal: Bring the clinical benefit of TriTACs to tumors that don’t express tumor specific antigens Approach: Develop a TriTAC prodrug that is inert in circulation and only active in tumors Benefits: Improved the
Slide 43: ProTriTAC Is Based on Clinically Validated TriTAC Components
ProTriTAC Is Based on Clinically Validated TriTAC Components αALB αTarget αCD3 TriTAC ProTriTAC protease linker (red) masking moiety from αALB (orange) αALB αTarget αCD3 Starting point is a TriTAC Binders are rearranged Protease linker and masking moiety added
Slide 44: ProTriTAC Increases Therapeutic Index by Linking Prodrug Activation to Half-Life Extension
αALB αTarget αCD3 Long-lived, inactive prodrug Rapid clearance in circulation TUMOR CIRCULATION CIRCULATION Activation by tumor proteases & T cell-directed killing ProTriTAC Increases Therapeutic Index by Linking Prodrug Activation to Half-Life Extension Albumin
Slide 45: ProTriTAC Is a Robust T Cell Engager Prodrug Platform
ProTriTAC Is a Robust T Cell Engager Prodrug Platform Consistent Masking in Vitro Superior PK Properties In Vivo Cell Killing Assay Non-Human Primate PK Prodrug Active drug Active drug Prodrug Reliable “plug-and-play” masking across multiple targets = platform established No accumulation of active d
Slide 46: ProTriTAC Has Improved Therapeutic Index In Vivo
ProTriTAC Has Improved Therapeutic Index In Vivo Better Efficacy in Mouse Better Safety in Non-Human Primates Control TriTAC ProTriTAC Both TriTAC and ProTriTAC dosed at 100 µg/kg Peak Cytokine Levels Both TriTAC and ProTriTAC dosed at 30 µg/kg Established Tumor Xenograft Model TriTAC ProTriTAC Impr
Slide 47: ProTriTAC: T Cell Engagers with Improved Therapeutic Index
ProTriTAC: T Cell Engagers with Improved Therapeutic Index Developed unique and robust prodrug approach Single proteolytic cleavage for efficient prodrug conversion and to maintain efficacy Novel activation mechanism to avoid accumulation of activated drug Expanded therapeutic index in vivo Efficacy
Slide 48: Conclusions and 2020 Milestones
Conclusions and 2020 Milestones Jerry McMahon, Ph.D., President and CEO
Slide 49: Anticipate Four TriTAC Product Candidates in the Clinic in 2020
Anticipate four TriTAC product candidates in the clinic in 2020 Clinical Milestones Milestone Timing HPN424: Preliminary Phase 1 data January 2019 HPN536: Initiate Phase 1/2a clinical trial April 2019 HPN217: Submit IND H2 2019 HPN217: Initiate Phase 1/2 clinical trial April 2020 HPN424: Presentatio
Harpoon Therapeutics — Technical Presentation (May 2020) on 6ix